[go: up one dir, main page]

CO2018013104A2 - Polipéptidos de fusión cd40l-fc y sus métodos de uso - Google Patents

Polipéptidos de fusión cd40l-fc y sus métodos de uso

Info

Publication number
CO2018013104A2
CO2018013104A2 CONC2018/0013104A CO2018013104A CO2018013104A2 CO 2018013104 A2 CO2018013104 A2 CO 2018013104A2 CO 2018013104 A CO2018013104 A CO 2018013104A CO 2018013104 A2 CO2018013104 A2 CO 2018013104A2
Authority
CO
Colombia
Prior art keywords
cd40l
methods
fusion polypeptides
fusion protein
antibody
Prior art date
Application number
CONC2018/0013104A
Other languages
English (en)
Inventor
Manuel Baca
Stacey Drabic
Ronald Herbst
Peter Emtage
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of CO2018013104A2 publication Critical patent/CO2018013104A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)

Abstract

En la presente se proporciona una proteína de fusión CD40L-Fc y métodos para utilizar la proteína de fusión en el tratamiento del cáncer que comprenden administrar la proteína de fusión CD40L-Fc o la proteína de fusión CD40L-Fc combinada con uno o más inhibidores de puntos de control inmunitario (por ejemplo, un anticuerpo anti-CTLA4 o anticuerpo anti-PD-L1).
CONC2018/0013104A 2016-05-13 2018-12-04 Polipéptidos de fusión cd40l-fc y sus métodos de uso CO2018013104A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662336129P 2016-05-13 2016-05-13
PCT/US2017/032352 WO2017197231A1 (en) 2016-05-13 2017-05-12 Cd40l-fc fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2018013104A2 true CO2018013104A2 (es) 2018-12-14

Family

ID=60267851

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0013104A CO2018013104A2 (es) 2016-05-13 2018-12-04 Polipéptidos de fusión cd40l-fc y sus métodos de uso

Country Status (18)

Country Link
US (1) US10975155B2 (es)
EP (1) EP3455263A4 (es)
JP (1) JP2019523636A (es)
KR (1) KR20190004319A (es)
CN (1) CN109153729A (es)
AR (1) AR108468A1 (es)
AU (1) AU2017264944A1 (es)
BR (1) BR112018072953A2 (es)
CA (1) CA3022636A1 (es)
CL (1) CL2018003141A1 (es)
CO (1) CO2018013104A2 (es)
IL (1) IL262727A (es)
MA (1) MA44993A (es)
MX (1) MX2018013762A (es)
RU (1) RU2018138703A (es)
SG (1) SG11201809374VA (es)
TW (1) TW201741337A (es)
WO (1) WO2017197231A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2310509T3 (pl) * 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
RU2701327C2 (ru) * 2013-09-11 2019-09-25 Медиммьюн Лимитед Антитела к b7-h1 для лечения опухолей
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
IL267861B2 (en) 2017-01-05 2025-02-01 Kahr Medical Ltd PD1-41BBL conjugated protein and methods of using the same
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
SG11202013167UA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
SG11202013170RA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof
US20220135649A1 (en) * 2019-02-06 2022-05-05 The Regents Of The University Of California Dominant negative cd40l polypeptides
KR20210006301A (ko) * 2019-07-08 2021-01-18 주식회사 프로젠 신규 융합단백질 및 그의 용도
KR20220058601A (ko) * 2019-09-05 2022-05-09 아스트라제네카 아베 확장 병기 소세포 폐암(es-sclc)을 치료하기 위한 조성물 및 방법
CN115087464B (zh) * 2019-12-13 2025-02-25 科优基因公司 新型白介素-15(il-15)融合蛋白及其用途
US20230123454A1 (en) * 2020-01-23 2023-04-20 Genexine, Inc. Fusion protein comprising pd-l1 protein and use thereof
EP4161536A4 (en) * 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
MX2023010703A (es) * 2021-03-12 2023-11-28 Janssen Biotech Inc Composiciones de proteínas de fusión inmunorreguladoras diseñadas por bioingeniería.
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
CN120917139A (zh) 2023-04-05 2025-11-07 豪夫迈·罗氏有限公司 用于抗体表达细胞的体外培养方法
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2222914C (en) * 1995-06-07 2002-04-02 Immunex Corporation Novel cd40l mutein
IL127884A0 (en) * 1996-07-08 1999-10-28 Univ Columbia Agents for inhibiting activation of cells bearing C40 on the cell surface selection and use thereof
US6774225B2 (en) 1999-04-15 2004-08-10 Hong Kong University Of Science & Technology Antigenized antibody vaccine for foot-and-mouth disease
WO2002008293A2 (en) * 2000-07-25 2002-01-31 Immunomedics Inc. Multivalent target binding protein
MXPA04005909A (es) * 2001-12-21 2005-05-17 Immunex Corp Polipeptidos recombinantes.
CN101213214B (zh) * 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
PL2310509T3 (pl) 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
JP6738831B2 (ja) * 2015-05-04 2020-08-12 アポジェニックス アーゲー 単鎖ｃｄ４０受容体アゴニストタンパク質

Also Published As

Publication number Publication date
EP3455263A4 (en) 2020-01-01
CL2018003141A1 (es) 2018-12-28
IL262727A (en) 2018-12-31
SG11201809374VA (en) 2018-11-29
JP2019523636A (ja) 2019-08-29
RU2018138703A (ru) 2020-06-15
AR108468A1 (es) 2018-08-22
EP3455263A1 (en) 2019-03-20
MA44993A (fr) 2019-03-20
CN109153729A (zh) 2019-01-04
US10975155B2 (en) 2021-04-13
US20170327588A1 (en) 2017-11-16
CA3022636A1 (en) 2017-11-16
KR20190004319A (ko) 2019-01-11
MX2018013762A (es) 2019-03-28
TW201741337A (zh) 2017-12-01
WO2017197231A1 (en) 2017-11-16
BR112018072953A2 (pt) 2019-02-19
AU2017264944A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
CO2018013104A2 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
CL2018002998A1 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CO2017000754A2 (es) Anticuerpo monoclonal anti-ctla4 o fragmento de unión a antígeno del mismo, y una composición farmacéutica del mismo
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
PE20170503A1 (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso
CL2019000694A1 (es) Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista de péptido de tlr para tratamiento de cáncer colorrectal.
MX2016012880A (es) Cadena j modificada.
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
BR112018070183A2 (pt) neoantígenos e métodos de seu uso
BR112018003339A8 (pt) Anticorpos antimesotelina completamente humanos e células imunoefetoras que direcionam mesotelina
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
UY35964A (es) Anticuerpos humanos para pd?1
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
CO2019011640A2 (es) Métodos y composiciones para la reducción de la inmunogenicidad
MX2020009465A (es) Anticuerpos anti-klk5 y metodos de uso.
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda